

## Special Issue

# Urologic Cancer: Endoscopic, Laparoscopic, and Robot-Assisted Surgery Management

### Message from the Guest Editor

The recent advances in robot-assisted urologic surgery have changed the quality of life for patients with urologic malignancy, such as prostate cancer, bladder cancer, and kidney cancer, with less invasive surgery, less blood loss, and better functional preservation. Importantly, the diagnostic value may also be changed by the recent developments in radical surgery. However, the impact of the development of such surgical modality is not fully assessed because of the paucity of data and short follow-up period. The comparison among radiologic, open, laparoscopic, and robot-assisted surgery has not been sufficiently investigated. Moreover, transurethral and endoscopic approaches to cancer lesions have also been developed in this decade. This Special Issue calls for clinical studies and reviews on any topic in “Endoscopic, Laparoscopic, and Robot-Assisted Surgery Management”.

### Guest Editor

Dr. Kouji Izumi

Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8640, Ishikawa, Japan

### Deadline for manuscript submissions

closed (1 March 2025)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/138057](https://mdpi.com/si/138057)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)